CD274 and neoplasm: Nivolumab is a fully humanized monoclonal IgG4 antibody that targets the programmed death 1 (PD-1) receptor, an immune checkpoint expressed on exhausted effector T lymphocytes, and prevents binding by its activating ligand PD-L1, leading to reinvigoration of anti-tumor immunity [14].